Search
Dr Luis Aznar-Garcia

Dr Luis Aznar-Garcia

Clinical oncology 07450672

  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Overview
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Bone
  • Brain/CNS
  • Breast
  • Gynaecology
  • Hepatobiliary
  • Lung
  • Urology

Offers

  • Face-to-face consultations
  • Video and telephone consultations

About me

I am currently working as a Consultant Clinical Oncologist at the Nottingham University Hospitals as Stereotactic Radiosurgery (SRS) and Brain Metastases MDT Lead Clinician. I also treat patients with Stereotactic Ablative Radiotherapy (SABR/SBRT) for Oligometastases, Hepatobilliary (HpB) tumours and breast cancer. I have set up the East Midlands Brain Metastases MDT and SRS Service.
I have a broad experience in the field of high advanced radiotherapy treatments. My main expertise is in the area of the Stereotactic Radiotherapy (SRS and SABR/SBRT), with a vast professional experience using Gammknife, Cyberknife, Magnetic Resonance Image Guided Radiotherapy (MRL) and Linac-based platforms to treat metastatic disease as well as primary tumours. I have treated with Stereotactic techniques more than 1000 patients since 2001.
I have been Head of Radiotherapy Department at Leicester University Hospitals for 3 years and Head of Radiotherapy and Radiosurgery at Ruber International Hospital (Madrid, Spain) for 2 years. I have been a Clinical Oncologist Consultant for more than 20 years.
I have been for several years Genesis Care UK SABR Clinical Advisor and SRS Clinical Lead, setting up the SRS Service at Oxford Genesis Care.
I am Honorary (Consultant) Assistant Professor at University of Nottingham.
I am member of multiple National and International Oncological Societies (ESTRO, ISRS, ESMO, RCR, SEOR…).
I am Editor of several International Oncological Journals.
I have published around 39 papers in International Medical Journals, books and meeting presentations.
I am Investigator in several Stereotactic Radiotherapy Trials (CORE, ABC-07, OligoRare, SARON, HALT, SPARC, SCALOP 2), some of them as Principal Investigator.
I have presented dozens of abstracts in Congresses, presentations in International meetings, and attended relevant Conferences.
I was awarded with the UK 1st Prize Macmillan Innovation Excellence Award 2019 for East Midlands Brain Metastases/SRS Service.

Areas of interest

Brain Stereotactic Radiosurgery (SRS) (metastases and primary tumours); Neuro Oncology: Stereotactic Ablative Radiosurgery (SABR) for Oligometastasis; Hepatobiliary cancers (pancreas and liver cancer); Breast Cancer; Cancer; Lung cancer; Lymph Node Tumours; Adrenal Tumours; Brain Metastasis; SABR for Lung Cancer;

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • A1080

    Stereotactic radiotherapy (SRT), second to fifth sessions, including adjustments, using Cyberknife or similar SRT technology - (5-50)

    Park Hospital (The) (5-50)

  • X0007

    Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (5-50)

    Park Hospital (The) (5-50)

  • X6950

    Clinical supervision of the planning of stereotactic radiosurgery e.g. SRT/SBRT and Gamma Knife - (5-50)

    Park Hospital (The) (5-50)

  • X6772

    Preparation for complex radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (5-50)

    Park Hospital (The) (5-50)

  • A0380

    Stereotactic radiotherapy (SRT) using GammaKnife or similar SRT technology - (5-50)

    Park Hospital (The) (5-50)

  • A1070

    Stereotactic radiotherapy (SRT), first/sole session using Cyberknife or similar SRT technology - (1-5)

    Park Hospital (The) (1-5)

  • Show All (8 )...
Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.